REFERENCES
1. Buhtoiarov IN. Pediatric Lymphoma.Pediatr Rev 2017; 38: 410-423.
2. Thanarajasingam G, Bennani-Baiti N,
Thompson CA. PET-CT in Staging, Response Evaluation, and Surveillance of
Lymphoma. Curr Treat Options Oncol 2016; 17: 24.
3. Kelly KM. Hodgkin lymphoma in
children and adolescents: improving the therapeutic index. Blood2015; 126: 2452-2458.
4. Schwartz CL, Constine LS, Villaluna
D et al. A risk-adapted, response-based approach using ABVE-PC for
children and adolescents with intermediate- and high-risk Hodgkin
lymphoma: the results of P9425. Blood 2009; 114: 2051-2059.
5. Kelly KM, Cole PD, Pei Q et al.
Response-adapted therapy for the treatment of children with newly
diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the
Children’s Oncology Group. Br J Haematol 2019; 187: 39-48.
6. Kahn JM, Kelly KM, Pei Q et al.
Survival by Race and Ethnicity in Pediatric and Adolescent Patients With
Hodgkin Lymphoma: A Children’s Oncology Group Study. J Clin Oncol2019; 37: 3009-3017.
7. Brepoels L, Stroobants S. PET
scanning and prognosis in Hodgkin’s lymphoma. Curr Opin Oncol2008; 20: 509-516.
8. Bhojwani D, McCarville MB, Choi JK
et al. The role of FDG-PET/CT in the evaluation of residual disease in
paediatric non-Hodgkin lymphoma. Br J Haematol 2015; 168:
845-853.
9. Fallanca F, Alongi P, Incerti E et
al. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end
of treatment of HL and NHL: a comparison of the Deauville Criteria (DC)
and the International Harmonization Project Criteria (IHPC). Eur J
Nucl Med Mol Imaging 2016; 43: 1837-1848.
10. Barnes JA, LaCasce AS, Zukotynski
K et al. End-of-treatment but not interim PET scan predicts outcome in
nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol 2011; 22:
910-915.
11. Isik EG, Kuyumcu S. Prediction of
outcome in pediatric Hodgkin lymphoma based on interpretation of
(18)FDG-PET/CT according to DeltaSUVmax, Deauville 5-point scale and IHP
criteria. 2017; 31: 660-668.
12. Ferrari C, Niccoli Asabella A,
Merenda N et al. Pediatric Hodgkin Lymphoma: Predictive value of interim
18F-FDG PET/CT in therapy response assessment. Medicine
(Baltimore) 2017; 96: e5973.
13. Brepoels L, Stroobants S, De
Wever W et al. Aggressive and indolent non-Hodgkin’s lymphoma: response
assessment by integrated international workshop criteria. Leuk
Lymphoma 2007; 48: 1522-1530.
14. Brepoels L, Stroobants S, De
Wever W et al. Hodgkin lymphoma: Response assessment by revised
International Workshop Criteria. Leuk Lymphoma 2007; 48:
1539-1547.
15. Meignan M, Gallamini A, Meignan M
et al. Report on the First International Workshop on Interim-PET-Scan in
Lymphoma. Leuk Lymphoma 2009; 50: 1257-1260.
16. Gallamini A, Fiore F, Sorasio R,
Meignan M. Interim positron emission tomography scan in Hodgkin
lymphoma: definitions, interpretation rules, and clinical validation.Leuk Lymphoma 2009; 50: 1761-1764.
17. Boellaard R, O’Doherty MJ, Weber
WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET
imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37:
181-200.
18. Furth C, Amthauer H, Hautzel H et
al. Evaluation of interim PET response criteria in paediatric Hodgkin’s
lymphoma–results for dedicated assessment criteria in a blinded
dual-centre read. Ann Oncol 2011; 22: 1198-1203.
19. Gobbi PG, Ferreri AJ, Ponzoni M,
Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol 2013; 85:
216-237.
20. Marr K, Ronsley R. Ifosfamide,
gemcitabine, and vinorelbine is an effective salvage regimen with
excellent stem cell mobilization in relapsed or refractory pediatric
Hodgkin lymphoma. 2020; 67: e28167.
21. Henderson TO, Parsons SK,
Wroblewski KE et al. Outcomes in adolescents and young adults with
Hodgkin lymphoma treated on US cooperative group protocols: An adult
intergroup (E2496) and Children’s Oncology Group (COG AHOD0031)
comparative analysis. Cancer 2018; 124: 136-144.
22. Kelly KM, Sposto R, Hutchinson R
et al. BEACOPP chemotherapy is a highly effective regimen in children
and adolescents with high-risk Hodgkin lymphoma: a report from the
Children’s Oncology Group. Blood 2011; 117: 2596-2603.
23. Cheson BD, Pfistner B, Juweid ME
et al. Revised response criteria for malignant lymphoma. J Clin
Oncol 2007; 25: 579-586.
24. Lopci E, Mascarin M, Piccardo A
et al. FDG PET in response evaluation of bulky masses in paediatric
Hodgkin’s lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004
trial. Eur J Nucl Med Mol Imaging 2019; 46: 97-106.
25. Cheson BD, Fisher RI, Barrington
SF et al. Recommendations for initial evaluation, staging, and response
assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano
classification. J Clin Oncol 2014; 32: 3059-3068.
26. Schaefer NG, Taverna C, Strobel K
et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line
therapy–is biopsy of FDG-avid lesions still needed? Radiology2007; 244: 257-262.
27. Jorgov L, Montravers F, Balogova
S et al. Paediatric and adolescent Hodgkin lymphoma: information derived
from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment
and on interim PET/CT. Eur J Nucl Med Mol Imaging 2016; 43:
1220-1230.
28. Zhang X, Fan W, Xia ZJ et al. Use
of subsequent PET/CT in diffuse large B-cell lymphoma patients in
complete remission following primary therapy. Chin J Cancer 2015;
34: 70-78.
29. Ilivitzki A, Radan L, Ben-Arush M
et al. Early interim FDG PET/CT prediction of treatment response and
prognosis in pediatric Hodgkin disease-added value of low-dose CT.Pediatr Radiol 2013; 43: 86-92.
30. Cerci JJ, Pracchia LF, Linardi CC
et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival
in early and advanced Hodgkin lymphoma. J Nucl Med 2010; 51:
1337-1343.
31. Engert A, Haverkamp H, Kobe C et
al. Reduced-intensity chemotherapy and PET-guided radiotherapy in
patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a
randomised, open-label, phase 3 non-inferiority trial. Lancet2012; 379: 1791-1799.
32. Chang Y, Fu X, Sun Z et al.
Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in
extranodal natural killer/T-cell lymphoma patients treated with
L-asparaginase/pegaspargase. Sci Rep 2017; 7: 41057.
33. Hu YY, Zhang X, Long W et al.
Cervical lymph node hyperplasia on [(18)F]-fluorodeoxyglucose
positron emission tomography/computed tomography scan after treatment of
children and adolescents with malignant lymphoma. Eur J Radiol2015; 84: 1378-1382.
34. Bakhshi S, Bhethanabhotla S,
Kumar R et al. Posttreatment PET/CT Rather Than Interim PET/CT Using
Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A
Prospective Study Comparing PET/CT with Conventional Imaging. J
Nucl Med 2017; 58: 577-583.
35. Kluge R, Chavdarova L, Hoffmann M
et al. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment
Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy
(OEPA) in Hodgkin’s Lymphoma. PLoS One 2016; 11: e0149072.
36. Cheson BD. The International
Harmonization Project for response criteria in lymphoma clinical trials.Hematol Oncol Clin North Am 2007; 21: 841-854.
37. Barrington SF, Qian W, Somer EJ
et al. Concordance between four European centres of PET reporting
criteria designed for use in multicentre trials in Hodgkin lymphoma.Eur J Nucl Med Mol Imaging 2010; 37: 1824-1833.